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Aims The ŒDIPE trial examined the safety and efﬁcacy of an abbreviated hospitalization after implan-
tation or replacement of dual-chamber pacemakers (PM) using a telecardiology-based ambulatory
surveillance programme.
Methods and results Patients were randomly assigned to (i) an active group, discharged from the
hospital 24 h after a ﬁrst PM implant or 4–6 h after replacement, and followed for 4 weeks with
Home-Monitoring (HM), or (ii) a control group followed for 4 weeks according to usual medical practices.
The primary objective was to conﬁrm that the proportion of patients who experienced one or more
major adverse events (MAE) was not higher in the active than in the control group. The study included
379 patients. At least one treatment-related MAE was observed in 9.2% of patients (n ¼ 17) assigned to
the active group vs. 13.3% of patients (n ¼ 26) in the control group (P ¼ 0.21), a 4.1% absolute risk
reduction (95% CI 22.2 to 10.4; P ¼ 0.98). By study design, the mean hospitalization duration was
34% shorter in the active than in the control group (P , 0.001), and HM facilitated the early detection
of technical issues and detectable clinical anomalies.
Conclusion Early discharge with HM after PM implantation or replacement was safe and facilitated the
monitoring of patients in the month following the procedure.
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Introduction
Telecardiology is offering new choices for the long-term
surveillance of cardiac pacemakers (PM) and automatic
deﬁbrillators. Home-Monitoring
w (HM) (Biotronik GmbH &
Co. KG, Berlin, Germany) is a proven telecardiology
system, which enables the remote follow-up of these
devices, either continuously, for the early detection of
adverse clinical or technical events, or intermittently, as a
substitute for scheduled follow-up ofﬁce visits.
1–7 The OnE
Day pacemaker Implantation Program with homE-monitoring
(OEDIPE) trial was conducted to examine the safety and
effectiveness of HM when implemented during the relatively
high-risk ﬁrst month that follows the primary implantation
or replacement of the dual-chamber PM.
Methods
Primary study objective
The primary objective of the OEDIPE trial was to determine
whether, by continuously monitoring all parameters of device func-
tion, this telecardiology system enables a signiﬁcant shortening
of post-operative hospitalization, while preserving a safety level
equivalent to that associated with conventional management,
usually associated with a longer hospital stay. The primary study
objective was to conﬁrm that the proportion of patients who experi-
enced one or more major adverse events (MAE) was not higher in
the group of patients assigned to early discharge from the hospital
with HM (active group) than in a control group. Early discharge
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(ii) within 4–6 h after pulse generator replacement.
Secondary objectives
The secondary objectives of the trial included (i) an evaluation of
the performance of telecardiology in the detection of pacing
system dysfunction, (ii) a comparison of the duration of hospitaliz-
ation between the two study groups, (iii) an estimation of the puta-
tive cost saving associated with device implantation in the group
assigned to shorter hospitalization, and (iv) a measurement of the
possible impact of telecardiology on quality of life.
8
Telecardiology system
All patients included in this trial underwent implantation of a Philos
II DR-T PM (Biotronik), equipped with telecardiology, a system
capable of automatically transmitting the data stored in implanta-
ble devices. Enrolment was limited to recipients of the dual-
chamber PM, as, when the study was conducted, HM had not been
installed in single chamber devices. The pulse generator includes
a radiofrequency circuitry and an antenna, which emit the data
daily to the Cardio-Messengerw. This base station automatically
re-routs the data over a wireless global system for mobile communi-
cations (GSM) network to the Biotronik service centre. After an
automatic analysis, the data (daily messages) are made available
on a secure Internet site to the physician responsible for the
patient. In case of clinical or technical anomaly (or both), the
device emits additional warning messages, which are immediately
delivered via the service centre to the physician, by e-mail,
fac simile, or text messages, or by all three means (Table 1).
Patient selection
The criteria for inclusion in the OEDIPE trial were: (i) age .18 years;
(ii) indication for ﬁrst implant or replacement of a dual-chamber
pulse generator; (iii) patient ability to comply with the study protocol
and signature of an informed consent; (iv) stable medical and resi-
dential status; (v) ability to discharge the patient from the hospital
1 day after ﬁrst device implant, or on the day of pulse generator
replacement; (vi) absence of exclusion criterion. To optimize the
safety of the trial and facilitate compliance with the protocol,
patients were excluded if they (i) had a spontaneous ventricular
rate ,30 b.p.m.; (ii) were in overt heart failure; (iii) had a history
of cardiac surgery or myocardial infarction within 1 month; (iv)
were systemically anticoagulated; (v) were unable to understand
telecardiology; (vi) lived in an area with insufﬁcient GSM coverage.
Study protocol
OEDIPE was a randomized, open-label, parallel- and non-inferiority
design trial in which 38 French and 1 Belgian medical centres par-
ticipated, including 22 public and 17 private institutions (appen-
dices). The trial protocol, which complied with the declaration of
Helsinki, was reviewed and approved by the pertinent National
Ethics Committees, and all patients granted their written informed
consent to participate. Patients who fulﬁlled the inclusion criteria
and indications for permanent pacing described in the guidelines
issued by professional societies were randomly assigned to an
active vs. a control group by means of sealed envelopes.
9
In the absence of interim adverse event (AE), patients assigned to
the active group were discharged 24 h after a ﬁrst implant or 4–6h
after the replacement of the pulse generator. In patients who had
undergone subclavian puncture, a chest radiograph was obtained
before their discharge from the hospital. Patients in this group were
monitored daily by telecardiology, with option of one or more visits
by a home nurse.
10 The data transmitted were analysed daily through-
out the trial. In the event of a device dysfunction (technical issue) or
clinical event (medical issue), the cardiologist investigator was noti-
ﬁed by e-mail, fac simile, or text message, allowing the rescheduling
of the next follow-up visit, if necessary. It is noteworthy, however,
that HM was not a substitute for emergency medical services.
Patients in the control group were managed according to the
usual practice of each participating medical centre and discharged
on the basis of their medical status and institutional guidelines.
Although transmitted daily, these telecardiology data were not
made available to the investigators and were analysed retrospec-
tively. The option of one or more visits by a home nurse was
also available. The general design of the trial is shown in Figure 1.
Table 1 Technical and clinical information transmitted daily, along with corresponding warnings in case of detected anomaly
Daily transmission Associated warning messages Device programming in both study groups
Technical information DDD or DDDR mode
Battery status Elective replacement indicator
Atrial lead impedance Atrial lead impedance ,200 or .3000 V Automatic atrial lead test: ON
Ventricular lead impedance Ventricular lead impedance ,200 or .3000 V Automatic ventricular lead test: ON
R wave safety margin R wave safety margin ,50%
P wave safety margin P wave safety margin ,50%
Ventricular capture threshold Autothreshold deactivated Autothreshold: ON
Variations in ventricular threshold .1V
Ventricular threshold .2.4 V
No transmission No transmission in last 36 h Transmission at 3:00 a.m.
Clinical information
Mean ventricular rate/24 h
Number and duration of mode switch Mode switch duration .18 h Mode switch: DDIR/160 b.p.m. (X/Z 5/8)
Number and type of atrial arrhythmia First mode switch since onset of follow-up
Peak ventricular rate during mode switch IEGM recording for mode switch: ON
Daily peak ventricular rate IEGM recording for ventricular rate: ON
Duration of episode with fastest
ventricular rate
Ventricular rate .160 b.p.m.
Number of ventricular salvos
Number of ventricular episodes Ventricular episode (.8 consecutive PVC)
Peak hourly/daily rate of PVC
PVC, premature ventricular complex; IEGM, intracardiac electrogram.
The OEDIPE trial 1393At the end of the trial, 30 days after inclusion of the patient, or at
the time of an additional follow-up visit, the investigator interro-
gated the pacing system and recorded the possible occurrence of
an AE. In the event of MAE, a report was ﬁled within 24 h to the
Safety Monitoring Committee (SMC), which comprised the Principal
Investigator and two medical experts (appendices). Quality of life
was estimated at the end of the study by means of an SF-36 ques-
tionnaire.
11 Cost of care was calculated in both study groups by
review of the billing documents for private medical institutions
and by compilation of customary reimbursement costs for the
public medical centres.
Deﬁnitions of adverse events
Major adverse event was deﬁned as an event experienced by a
patient, related to the PM implant procedure or the underlying
medical condition, prompting an intervention, and with serious or
potentially serious consequences, including death, change in prog-
nosis, prolongation of hospitalization for peri- or post-operative
complications, and re-admission to the hospital. Non-major AE
(NMAE) was deﬁned as an event related to the PM implant procedure
or the underlying medical condition without serious or potentially
serious consequences, such as prolongation of hospitalization or
the need to re-admit the patient to the hospital. For example, an
episode of atrial ﬁbrillation might have been classiﬁed as MAE or
NMAE depending on its tolerability and need for continued or repeti-
tive in-hospital care. Adverse events unrelated to the PM implant
procedure or to the underlying medical condition were not included
in this analysis. All AE that occurred in the active group were
reported to the SMC.
Statistical analyses
On the basis of a primary non-inferiority hypothesis and an 80%
power (1-b), we estimated that a sample of 400 patients needed
to be enrolled to reach a 5% signiﬁcance level (a error), assuming
a 10% rate of non-compliance and 5% equivalence margin. The
patients were randomly assigned to an active vs. a control group
by means of sealed envelopes in even blocks among study centres.
Comparisons between the two study groups were made by Fisher’s
exact test and x
2 test for nominal, qualitative variables and by
Student’s parametric test for normal distributions of quantitative,
continuous, and discrete variables. Absolute risk reduction (RR)
and 95% conﬁdence intervals (CI) were calculated. A P-value
,0.05 was considered signiﬁcant.
Results
Patient population
Between April 2005 and December 2006, 406 patients were
initially included in the trial. After the exclusion of (i) two
enrolling centres because of randomization and protocol
violations, and (ii) seven patients because of exclusion
Table 2 Underlying heart disease, disease manifestations and
electrocardiographic indications for pacing in each study group
Study groups P
Active
(n ¼ 184)
Control
(n ¼ 195)
Underlying heart disease
Primary conduction system
disease
31.1 25.9 0.21
None known 39.9 46.3 0.2
Hypertensive 7.3 9 0.54
Ischaemic 6.7 4.5 0.33
Cardiomyopathy 3.6 5 0.51
Congenital 1.6 0 0.07
Disease manifestations
None 14.5 9.4 0.1
Syncope 44.5 38.2 0.18
Light-headedness 2.5 6.4 0.06
Dyspnoea 15 18 0.4
Fatigue 18 16.3 0.64
Palpitation 2.5 6 0.07
Others 3 5.6 0.19
Electrocardiographic indications
Bradycardia–tachycardia or
sick sinus syndrome
28.3 32.5 0.37
First- or second-degree
atrioventricular block
31.6 24.5 0.12
Third-degree
atrioventricular block
25.1 26 0.84
Missing information 2.7 4 0.47
Others 12.3 13 0.83
Values indicate percentage of patients in the corresponding group.
Figure 1 Overall study design.
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¼ 75+9.8 years, 61% men), of whom 184 were assigned
to the active and 195 to the control group. The baseline
clinical characteristics, similar in both study groups,
and the electrocardiographic observations prompting the
implantation of permanent PM, are shown in Table 2. The
percentages of ﬁrst pacing system implants (86 vs. 87%),
overall procedure duration (45+20 vs. 47+21 min), and
duration of ﬂuoroscopic exposure (4.3+4.1 vs. 5.0+
4.6 min) were also similar in both groups.
The mean duration of the trial was 31+6.3 days (range
7–89) following implantation of the pacing systems.
Adverse events
By the end of the trial, the proportion of patients with at
least one treatment-related AE was 19.5% (n ¼ 74) in the
overall population (95% CI 15.5–23.5), 20.1% (n ¼ 37) in
the active group, and 19.0% (n ¼ 37) in the control group
(absolute RR 1.1%; 95% CI 26.9 to 9.1; P¼0.78). At least
one treatment-related MAE (primary study endpoint) was
observed in 11.3% of patients (n ¼ 43) in the overall popu-
lation (95% CI 8.2–14.5), and in 9.2% of patients (n ¼ 17)
assigned to the active group, vs. 13.3% of patients (n ¼ 26)
in the control group. This 4.1% absolute RR (95% CI 22.2
to 10.4; P¼0.98) conﬁrmed the non-inferiority of the abbre-
viated hospitalization when compared with the standard
management programme. At least one treatment-related
NMAE was observed in 8.7% (n ¼ 33) of the overall
population (95% CI 5.9–11.5) and in 11.4% of patients (n ¼
21) assigned to the active group vs. 6.2% of patients (n ¼
12) in the control group (P ¼ 0.07).
There were 40 (17 technical and 23 medical) AE in the
active group vs. 38 (11 technical and 27 medical) in the
control group. The types of technical and medical AE that
occurred in the overall population and in each study group,
before and after discharge from the index hospitalization,
are detailed in Table 3. In the active group, 45% (18/40) of
all AE were MAE, vs. 68% (26/38) in the control group (P ¼
0.04). Conversely, the proportions of NMAE relative to all
AE were 55% (22/40) in the active group, vs. 32% (12/38) in
the control group (P ¼ 0.04). The cumulative incidence of
MAE and NMAE in each study group is shown in Figure 2.
Adverse events not included in the analysis
Twelve AE unrelated to the implantation procedure or to the
patient clinical presentation or management (one program-
mer dysfunction, eight miscellaneous organizational issues,
one surgical intervention for inguinal hernia, one convulsive
episode, and one acute urinary tract infection) were not
included in the analysis.
Implementation of telecardiology
Telecardiology was successfully implemented and oper-
ational in 346 of the 379 patients (91% of the overall
population). The transmission functions were implemented
Table 3 Technical and medical adverse events before/after discharge from the hospital in each study group
Adverse event All patients Active group Control group
Major
Technical
Lead dislodgement and twiddler syndrome 6/8 1/4 5/4
Intermittent pacing; undersensing 1/1 1/0 0/1
Medical
Death from lung cancer
a 0/1 0/0 0/1
Arrhythmia 12/2 5/2 7/0
Pneumothorax 1/0 1/0 0/0
Myocardial perforation and tamponade 4/0 3/0 1/0
Pulse generator pocket complications 1/3 0/1 1/2
Hypotension, hypertension, near-syncope, syncope 1/2 0/0 1/2
Acute pulmonary oedema 0/1 0/0 0/1
All major adverse events, before/after (total) 26/18 (44) 11/7 (18) 15/11 (26)
Non-major
Technical
Rise in ventricular capture threshold 0/2 0/2 0/0
Permanent atrial undersensing 0/4 0/4 0/0
Deactivation of autothreshold 2/2 2/2 0/0
Telemetry-related stress
a 0/2 0/1 0/1
Medical
Pulse generator pocket complication 0/1 0/1 0/0
Arrhythmia 1/7 0/3 1/4
Fever 1/0 1/0 0/0
Hypotension, light-headedness 2/1 2/0 0/1
Haematoma 6/2 3/0 3/2
Cutaneous allergic reaction 1/0 1/0 0/0
All non-major adverse events, before/after (total) 13/21 (34) 9/13 (22) 4/8 (12)
All adverse events 39/39 (78) 20/20 (40) 19/19 (38)
Values indicate numbers of observations before/after discharge from the hospital.
aNo associated telemetry transmission.
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cardiology and the end of the study, representing 24.0+9.3
days of follow-up and a total of 8144 transmissions.
In the active group, 12 patients (6.5%) from seven
centres sent no transmission because of the improper use
of the transmitter, including 10 devices that were turned
off or out of reach of the PM and two instances of unma-
nageable stress caused by the telecardiology system.
Excluding duplicate messages, 108 of the 172 patients
whose telecardiology was implemented transmitted a
total of 167 warning messages during the trial, with a
higher percentage of warnings prompted by medical than
by technical AE (Figure 3).
Management of patients by telecardiology
In the active group, after discharge of the patients
from the hospital, 12 warning messages (of which 2 were
accompanied by telephone communications) prompted
patient visits and the detection of 4 MAE and 8 NMAE,
representing 60% of the 20 AE observed in this group.
Technical issues prompted 9 of these 12 messages (75%).
A retrospective analysis including the overall population
revealed that 39 of the 78 AE occurred after discharge of
the patient from the hospital (Table 3). Among these 39
AE, 3 were not detectable because of absence of trans-
mission and 21 of the remaining 36 (58%) were detectable.
The additional workload imposed by the reception of an
estimated 1+1.5 messages/patient/month decreased to
0.5 message/patient/month past the ﬁfth day after the
implantation procedure.
After a warning issued by the device, the mean medical
reaction time, deﬁned as the time elapsed between the
reception of a ﬁrst warning message and the patient
contact, was 3.0+3.5 days for four MAE and 8.2+8.7
days for eight NMAE in the active group (prospective
analysis), vs. 6.6+10.0 days (n ¼ 5) and 17.5+11.6 days
(n ¼ 4), respectively, in the control group (retrospective
analysis). The mean medical reaction time for all 12 AE
observed in the active group was 6.5+7.6 days, vs.
11.4+11.6 days for the 9 AE observed in the control
group. Furthermore, in the active group, the mean advance-
ment of follow-up, deﬁned as the interval between the date
of supplemental patient visit and the date of routinely
Figure 3 Types of messages transmitted by 108 patients assigned to the active group.
Figure 2 Cumulative number of adverse events (AE) and major
adverse events (MAE), up to 35 days of follow-up, in each study group.
F. Halimi et al. 1396scheduled 1-month follow-up, was 20.0+1.6 days for MAE
and 12.0+9.3 days for NMAE.
Patients without warning messages
In the overall population of 346 patients with operational HM
systems, 139 (40.2%) transmitted no warning message.
Among these 139 patients, 6 experienced an MAE and 1
experienced an NMAE. The six MAE included two infected
pulse generator pockets, two hypotensive episodes, one
episode of acute pulmonary oedema, one atypical, non-
cardiovascular episode of malaise, and one haematoma.
Physicians were contacted by ﬁve patients for MAE. The
negative predictive value of the absence of warning by HM
was 94% (95% CI 91–98).
Duration of hospitalization
By study design, the mean duration of hospitalization was
34% shorter in the active than in the control group (95% CI
19–49%), corresponding to 1.6+4.9 fewer days (95% CI
0.9–2.3; P , 0.001) spent in the hospital (3.2+3.2 vs.
4.8+3.7 days). This shorter mean hospital stay was attribu-
table to a 49% shorter post-operative period in the active
group (95% CI 32–66%), corresponding to a gain of 1.4+
3.3 days (95% CI 0.89–1.85; P , 0.001) compared with the
control group (1.4+2.5 vs. 2.8+2.2 days). Thus, 87% of
patients left the hospital on the day of (for pulse generator
replacements) or the day after (for new systems) the
implantation procedure, in contrast with 29% of patients
managed by standard methods.
Cost analysis
The cost calculations were based on (i) the institutional and
patient care charges listed in the 2005 and 2006 ‘Groupe
Homoge `ne de Se ´jour dans le secteur public et prive ´’ publi-
cation, (ii) the billable items included on the ‘list of pro-
ducts and medical acts’ (costs of telecardiology excluded),
(iii) the medical and para-medical fees listed in the ‘Classi-
ﬁcation Commune des Actes Me ´dicaux’, (iv) the laboratory
costs (from the private sector billing contract), and (v) the
transportation costs (http://www.ameli.fr). Expenses
related to the Biotronik service centre were provided by
the manufacturer. The mean costs for the duration of the
trial were E7125+1543/patient for the 178 patients
assigned to the active group vs. E7414+1659 for the 187
patients assigned to the control group (P ¼ 0.08).
Quality-of-life estimates
The SF-36 quality-of-life questionnaire was completed at 1
month after the index implant procedure by 107 study
participants assigned to the active group and 110 patients
assigned to the control group. The mean psychological,
physical, and overall scores were 66+20, 60+20, and
64+19, respectively, in the active group vs. 68+18,
62+19, and 67+19, respectively, in the control group.
These differences were all statistically non-signiﬁcant.
Discussion
Telecardiology has unequivocally made positive contributions
to the follow-up of patients, particularly for recipients
of permanent PM, cardioverter deﬁbrillators, and cardiac
resynchronization devices. All manufacturers of implantable
devices are currently involved in developing and perfecting
these systems, which are all capable of remote consultations.
However, their implementation remains heterogeneous,
because of variable organizational or administrative factors
among countries, including reimbursement for telemedicine.
The HM system used in this trial allows a time-limited
follow-up of the functions of implanted devices, as well as
the continuous, daily surveillance of transmitted data,
which can be reviewed on a dedicated and secure Internet
site. A particularly notable characteristic of HM, besides its
scheduled transmissions, is the warning messages that are
issued in case of technical dysfunction or detectable clinical
abnormality and that are addressed to the physician in
charge of the patient via e-mail, fac simile, or text message
or via all these means of communication. These warnings
allow the anticipation and, when appropriate, the manage-
ment of potentially harmful medical events. It is, however,
noteworthy that HM is not a means of real-time management
of emergencies, rather than a close surveillance system.
OEDIPE was the ﬁrst trial designed to examine prospec-
tively the role that HM might play in the ﬁrst month after
implantation of pacing systems or replacement of pulse
generators. The increased risk of complications incurred in
the weeks following implants of PM, as well as the medical
and economic importance of shortening the hospital stay
after surgical procedures, is well known.
12,13 By study
design, nearly 90% of the patients in the active group were
discharged from the hospital within 24 h, compared with
,30% in the control group. Although overnight hospitaliz-
ations for ﬁrst implants and ambulatory replacements of
pulse generators have been implemented in experienced
medical centres, the mean post-operative hospital stay of
2.8 days in our control group indicates that these practices
did not represent standard care among the 39 centres
included in this study. The ability to remotely follow recipi-
ents of implanted devices post-operatively might facilitate
the shortening of hospital stays.
The proportion of patients with at least one treatment-
related MAE was similar in both study groups. This even
distribution between the two groups satisﬁed the primary
objective of the study, which was to conﬁrm that HM allowed
a signiﬁcant shortening of the post-procedural hospitalization,
while preserving a safety level similar to that associated
with standard patient care. It is noteworthy that whereas the
cumulative number of MAE was signiﬁcantly lower in the
active than inthe control group, that of NMAE was signiﬁcantly
higher, such that the overall number of AE was similar in both
groups. Instead of reﬂecting a higher morbidity, the higher
number of NMAE in the active group might be attributable to
the early detection of technical or clinical anomalies, which,
otherwise, might have remained unnoticed without telecar-
diology surveillance. It is also noteworthy that, in both
groups, 50% of the AE occurred in the hospital and could have
been detected without the assistance of HM (Table 3).
However, in theactivegroup, afterdischargefromthe hospital
andupto 30 days of follow-up,12 warning messagesprompted
theearlydetectionof4MAEand8NMAEoutofatotalof20AE.
The relatively high number of post-operative AE observed in
this study was probably due to the inclusion of events that
were not procedure-related, such as atrial or ventricular
arrhythmias. However, these rhythm disturbances developing
in the immediate post-operative period might be, in some
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non-cardiac death observed in this trial was not related to
the procedure, though was classiﬁed as MAE according to
the pre-speciﬁed deﬁnitions of our protocol. This single death
had no effect on the overall statistical outcome.
The retrospective analysis of the pooled data from the
two groups, including the data from the control group avail-
able a posteriori to the expert committee, showed that over
80% of the technical AE could have been detected early.
Although HM is sensitive in the detection of technical
complications and arrhythmic episodes, its sensitivity is
lower with respect to medical AE related to the surgical
procedure, such as pulse generator pocket complications
or development of a pneumothorax. Furthermore, warnings
may be non-speciﬁc, as a single anomaly may trigger several
different kinds of messages. From this perspective, HM is
not an automatic surveillance system, and its data must be
critically reviewed by the physician.
In the control group, the medical reaction time, based
strictly on overtly abnormal clinical manifestations, was
considerably longer than in the active group. The analysis
of AWARE, a retrospective study of .11 000 patients in 23
countries, revealed that AE occurred, on average, 26 days
after the last visit, advancing the diagnosis by a mean of
154 days.
14 In the OEDIPE trial, besides the surveillance
data routinely transmitted to the Internet site, an estimated
1+1.5 additional warning messages/patient/month were
issued during the study, decreasing to 0.5 warning
message/patient/month past the ﬁfth day of enrolment in
the trial, an estimate concordant with the 0.6 message/
patient/month reported during the long-term follow-up of
AWARE. The gradual decrease in the rate of warning mess-
ages following device implantation appears related to the
optimization of the alert settings and to the elimination of
warnings after a ﬁrst event, for example, a ﬁrst automatic
mode switch. It is noteworthy that 40% of the overall
patient population transmitted no warning message,
though seven patients did experience a medical AE that
could not have been detected by telecardiology. This
strongly suggests that the absence of warning message
excludes reliably the occurrence of undetected technical
AE. A similar 47% of patients regularly monitored by telecar-
diology transmitted no warning message in the AWARE study.
Although HM decreased the duration of post-operative
hospitalization by nearly 50% compared with the control
group, the decrease in overall costs associated with this
shortening of the hospital stay was not statistically signiﬁ-
cant, because of the reimbursement scheme based on
diagnosis-related groups. Finally, the SF-36 questionnaire
showed that telecardiology had no negative effect on the
patients’ quality of life.
The results of the OEDIPE trial, which combines abbre-
viated hospitalization with telecardiology follow-up after
the ﬁrst implant of pacing systems or replacement of pulse
generators, demonstrate that this programme was safe and
facilitated the monitoring of patients in the month following
the procedure.
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Nadji, MD, Centre Hospitalier Abbeville, Abbeville; Bouchaib
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